ClinicalTrials.gg
Active, not recruitingNCT06227494Updated Nov 19, 2026

Dietary Fiber: Is it the Missing Link in Achieving Long Term Behavior Change?

An interventional study of Fiber Intervention and Standard Weight Loss Education in Obesity, sponsored by Oklahoma State University. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Oklahoma State University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 19, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The overall objective of this three-arm randomized controlled trial is to compare a dietary fiber-focused behavioral intervention to standard weight loss education for improving eating-related behavior and cognition, weight, and metabolic markers of chronic disease risk in a population of adults with obesity.

02

Conditions studied

  • Obesity

Browse trials for

03

In context

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

This study's enrollment of 63 is close to the median of 67 across 9,043 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Oklahoma State University is the lead sponsor of 39 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-65 years of age
  • Dietary fiber intake ≤25 grams/day
  • Self-reported ≥30 kg/m2
  • Willingness to attend in-person education sessions
  • Willingness to avoid taking supplemental digestive aids (e.g., alpha-galactosidase (Beano®),
  • Willingness to provide .

Exclusion criteria

Exclusion Criteria:

  • Metabolic, digestive, or allergic conditions or reactions that preclude consumption of whole food or food groups (e.g., irritable bowel syndrome, diverticulosis)
  • History of gastric bypass surgery
  • Currently taking glucagon like glucagon-like peptide-1 (GLP-1) Receptor Agonists
  • Self-reported history of a diagnosed eating disorder
  • Chronic disease (other than obesity)
  • Pregnancy or lactation
  • Use of tobacco or electronic smoking products
  • Taking a pre-, pro-, or syn-biotic supplement
  • Enrollment in another weight loss or diet intervention
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Fiber Intervention

    Individuals in this arm will be given instruction on how to increase fiber intake,

    Behavioral: Fiber Intervention

  • Active comparator
    Standard Weight Loss Education

    Individuals in this arm will be given standard weight loss education

    Behavioral: Standard Weight Loss Education

  • Experimental
    Fiber Intervention + Standard Weight Loss Education

    Individuals in this arm will be given education on both fiber and standard weight loss

    Behavioral: Fiber Intervention · Behavioral: Standard Weight Loss Education

Interventions

  • BehavioralFiber Intervention

    Group education and phone-based motivational interviewing to gradually increase dietary fiber consumption to 30-35 grams per day.

  • BehavioralStandard Weight Loss Education

    Group education and phone-based motivational interviewing to promote current evidence-based behaviors to promote weight loss via achieving a negative energy balance.

06

What researchers measure

Primary outcomes

  1. Body weight

    Measure of body weight/mass

    Time frame: Measured at baseline (time 1, month 0), post-intervention (time 2, month 15), and post-observation (time 3, month 27)

Secondary outcomes

  1. Body composition (fat mass, lean mass)

    Dual x-ray absorptiometry (DEXA) scans

    Time frame: Measured at baseline (time 1, month 0) and post-observation (time 3, month 27)

  2. Fecal short chain fatty acids

    Taken from fecal samples collected at home

    Time frame: Measured at baseline (time 1, month 0), post-intervention (time 2, month 15), and post-observation (time 3, month 27)

  3. Fecal bacteria measured using 16S ribosomal ribonucleic acid (rRNA) sequencing

    Will include measures of diversity, abundance, etc.

    Time frame: Measured at baseline (time 1, month 0), post-intervention (time 2, month 15), and post-observation (time 3, month 27)

  4. Total Cholesterol

    Measured via blood samples (unit= milligram/deciliter (mg/dL))

    Time frame: Measured at baseline (time 1, month 0), post-intervention (time 2, month 15), and post-observation (time 3, month 27)

  5. Fasting blood glucose

    Measured via blood samples (unit=mg/dL)

    Time frame: Measured at baseline (time 1, month 0), post-intervention (time 2, month 15), and post-observation (time 33, month 27)

  6. Healthy Eating Index Scores measured using Health Eating Index 2020 (HEI-2020)

    Taken from 3 day diet records (score range=0-100, higher=better diet quality)

    Time frame: Measured at baseline (time 1, month 0), post-intervention (time 2, month 15), and post-observation (time 3, month 27)

  7. Three-Factor Eating Questionnaire

    Resulting scores in uncontrolled eating (range=9-36), cognitive restraint (range=3-12), and emotional eating (range=6-24); higher scores indicate more of that particular eating behavior

    Time frame: Measured at baseline (time 1, month 0), post-intervention (time 2, month 15), and post-observation (time 3, month 27)

  8. Implicit Association Test

    Represented with a total D variable (No range, but more negative = greater preference for unprocessed food)

    Time frame: Measured at baseline (time 1, month 0), post-intervention (time 2, month 15), and post-observation (time 3, month 27)

  9. Behavioral Inhibition System/Behavioral Approach System (BIS/BAS) Scale

    Score ranges from 20 to 80, with higher scores indicating greater behavioral inhibition and behavioral activation

    Time frame: Measured at baseline (time 1, month 0), post-intervention (time 2, month 15), and post-observation (time 3, month 27)

  10. Executive Function: Tower Test (Delis-Kaplan Executive Function System)

    Total Achievement Score (range=0-30, higher = higher executive function)

    Time frame: Measured at baseline (time 1, month 0), post-intervention (time 2, month 15), and post-observation (time 3, month 27)

  11. Executive Function: Color-Word Interference Test (Delis-Kaplan Executive Function System)

    Scaled inhibition/switching scores (score range=1-19, higher = higher executive function)

    Time frame: Measured at baseline (time 1, month 0), post-intervention (time 2, month 15), and post-observation (time 3, month 27)

  12. Skin Carotenoid scores measured via the Veggie Meter

    Veggie Meter; score range 0-800 (higher=greater skin carotenoids (i.e., consumption of more fruits/vegetables)

    Time frame: Measured at baseline (time 1, month 0), post-intervention (time 2, month 15), and post-observation (time 3, month 27)

  13. High-density lipoprotein (HDL) cholesterol

    Measured via blood samples (unit=mg/dL)

    Time frame: Measured at baseline (time 1, month 0), post-intervention (time 2, month 15), and post-observation (time 3, month 27)

  14. Low-density lipoprotein (LDL) cholesterol

    Measured via blood samples (unit=mg/dL)

    Time frame: Measured at baseline (time 1, month 0), post-intervention (time 2, month 15), and post-observation (time 3, month 27)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Mar 2028, 56 months after the start.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 56 months is above that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion Jan 2026 → Mar 2028 and completion Feb 2026 → Mar 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2023
First posted
Jan 29, 2024
StartActual
Jul 10, 2023
Primary completionEst.
Mar 20, 2028was Jan 2026
CompletionEst.
Mar 20, 2029was Feb 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jan 31, 2026→Mar 20, 2028
Nov 19, 2026
Study completion
Feb 28, 2026→Mar 20, 2029
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Primary completion Jan 31, 2026→Mar 20, 2028
    Study completion Feb 28, 2026→Mar 20, 2029
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06227494
Lead sponsor
Oklahoma State University
Responsible party
Sponsor
First posted
Jan 29, 2024
Start date
Jul 10, 2023
Primary completion
Mar 20, 2028 (estimated)
Completion
Mar 20, 2029 (estimated)
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion